EX-99.1 2 ea145263ex99-1_stratasysltd.htm PRESS RELEASE DATED AUGUST 5, 2021 ANNOUNCING THE FINANCIAL RESULTS OF STRATASYS LTD. FOR THE SECOND QUARTER ENDED JUNE 30, 2021

Exhibit 99.1

 

 

Stratasys Releases Second Quarter 2021 Financial Results

 

Revenue of $147.0 million
GAAP net loss of $20.2 million, or $0.31 per diluted share, and non-GAAP net loss of $1.6 million, or $0.02 per diluted share
Generated $5.6 million of cash from operations
Furthering penetration into Healthcare - introduced J5 MediJet medical 3D printer
$522.7 million cash and equivalents and no debt at quarter end

 

MINNEAPOLIS & REHOVOT, Israel--(BUSINESS WIRE) - August 5, 2021 Stratasys Ltd. (NASDAQ: SSYS) announced financial results for the second quarter of 2021.

 

Second Quarter 2021 Financial Results Summary Compared to Second Quarter 2020:

 

Revenue of $147.0 million compared to $117.6 million.
GAAP gross margin was 43.0%, compared to 37.2%.
Non-GAAP gross margin was 47.5%, compared to 45.4%.
GAAP operating loss was $22.7 million, compared to an operating loss of $29.3 million.
Non-GAAP operating loss was $2.6 million, compared to an operating loss of $8.1 million.
GAAP net loss was $20.2 million, or $0.31 per diluted share, compared to a net loss of $28.0 million, or $0.51 per diluted share.
Non-GAAP net loss was $1.6 million, or $0.02 per diluted share, compared to a net loss of $7.4 million, or $0.13 per diluted share.
Adjusted EBITDA was $3.5 million, compared to $(1.6) million.
Cash provided by operations of $5.6 million, compared to cash use of $9.7 million.

 

Dr. Yoav Zeif, Stratasys’s Chief Executive Officer stated, “Our strong second quarter results were highlighted by a 25% year over year revenue improvement with growth from all regions and all business lines. Our focus on manufacturing gained further traction, we increased the monetization and ecosystem partnerships of our software business, and we expanded our medical and dental offerings, advancing our plans for further penetration in the healthcare industry.”

 

Dr. Zeif continued, “The transition of the 3D printing industry from prototyping to mass production is ongoing, and our commitment to being the first choice in polymer 3D printing positions us to be the main benefactor. We are investing across technology, software, materials, and talent to capture increased market share that we expect will yield significant returns and sustained profitability in the years to come.”

 

Financial Outlook: (TBD)

 

Based on current market conditions and assuming that the impact related to the pandemic does not impede the economic environment further, the Company is reiterating and updating its outlook as follows:

 

Third quarter 2021 revenue of approximately 17% - 18% growth year-over-year. Fourth quarter revenue is expected to be sequentially higher than third quarter.

 

 

 

 

Full year operating expenses expected to rise approximately $30 million compared to 2020, primarily due to the return of employees to a full-time schedule starting January 1, 2021, as well as operating costs as the markets gradually re-open.
Full year capital expenditures anticipated to range from $24 million to $30 million.
Longer term, the Company continues to expect significant leverage benefit from its investments as revenue growth should start to accelerate in 2022 and beyond.

 

Stratasys Ltd. Second Quarter 2021 Webcast and Conference Call Details

 

The Company plans to webcast its conference call to discuss its second quarter 2021 financial results on Thursday, August 5, 2021 at 8:30 a.m. (ET).

 

The investor conference call will be available via live webcast on the Stratasys Web site at investors.stratasys.com, or directly at the following web address:

 

https://78449.themediaframe.com/dataconf/productusers/ssys/mediaframe/46027/indexl.html

 

To participate by telephone, the U.S. toll-free number is 877-407-0619 and the international dial-in is +1-412-902-1012. Investors are advised to dial into the call at least ten minutes prior to the call to register. The webcast will be available for six months at investors.stratasys.com, or by accessing the above-provided web address.

 

Stratasys is leading the global shift to additive manufacturing with innovative 3D printing solutions for industries such as aerospace, automotive, consumer products and healthcare. Through smart and connected 3D printers, polymer materials, a software ecosystem, and parts on demand, Stratasys solutions deliver competitive advantages at every stage in the product value chain. The world’s leading organizations turn to Stratasys to transform product design, bring agility to manufacturing and supply chains, and improve patient care.

 

To learn more about Stratasys, visit www.stratasys.com, the Stratasys blog, Twitter, LinkedIn, or Facebook. Stratasys reserves the right to utilize any of the foregoing social media platforms, including the company’s websites, to share material, non-public information pursuant to the SEC’s Regulation FD. To the extent necessary and mandated by applicable law, Stratasys will also include such information in its public disclosure filings.

 

Stratasys is a registered trademark and the Stratasys signet is a trademark of Stratasys Ltd. and/or its subsidiaries or affiliates. All other trademarks are the property of their respective owners.

 

2

 

 

 

Cautionary Statement Regarding Forward-Looking Statements

 

The statements in this press release regarding Stratasys’ strategy, and the statements regarding its projected future financial performance, including the financial guidance concerning its expected results for 2021, are forward-looking statements reflecting management’s current expectations and beliefs. These forward-looking statements are based on current information that is, by its nature, subject to rapid and even abrupt change. Due to risks and uncertainties associated with Stratasys’ business, actual results could differ materially from those projected or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the degree of our success at introducing new or improved products and solutions that gain market share; the degree of growth of the 3D printing market generally; the impact of potential shifts in the prices or margins of the products that we sell or services that we provide, including due to a shift towards lower margin products or services; the impact of competition and new technologies; potential further charges against earnings that we could be required to take due to impairment of additional goodwill or other intangible assets; the extent of our success at successfully consummating acquisitions or investments in new businesses, technologies, products or services; the strength and duration of, and degree of recovery from, the COVID-19 pandemic in the markets in which we operate; potential changes in our management and board of directors; global market, political and economic conditions, and in the countries in which we operate in particular (including risks related to the impact of coronavirus on our supply chain and business); costs and potential liability relating to litigation and regulatory proceedings; risks related to infringement of our intellectual property rights by others or infringement of others’ intellectual property rights by us; the extent of our success at maintaining our liquidity and financing our operations and capital needs; the impact of tax regulations on our results of operations and financial condition; and those additional factors referred to in Item 3.D “Key Information - Risk Factors”, Item 4, “Information on the Company”, Item 5, “Operating and Financial Review and Prospects,” and all other parts of our Annual Report on Form 20-F for the year ended December 31, 2020, which we filed with the U.S. Securities and Exchange Commission, or SEC, on March 1, 2021 (the “2020 Annual Report”). Readers are urged to carefully review and consider the various disclosures made throughout our 2020 Annual Report and the Reports of Foreign Private Issuer on Form 6-K that attach Stratasys’ unaudited, condensed consolidated financial statements and its review of its results of operations and financial condition, for the quarterly periods throughout 2021, which will be furnished to the SEC throughout 2021 (including on or about the date hereof), and our other reports filed with or furnished to the SEC, which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects. Any guidance provided, and other forward-looking statements made, in this press release are provided or made (as applicable) as of the date hereof, and Stratasys undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

 

Use of Non-GAAP Financial Measures

 

The non-GAAP data included herein, which excludes certain items as described below, are non-GAAP financial measures. Our management believes that these non-GAAP financial measures are useful information for investors and shareholders of our Company in gauging our results of operations (i) on an ongoing basis after excluding mergers, acquisitions and divestments related expense or gains and reorganization-related charges or gains, and (ii) excluding non-cash items such as stock-based compensation expenses, acquired intangible assets amortization, including intangible assets amortization related to equity method investments, impairment of long-lived assets and goodwill, revaluation of our investments and the corresponding tax effect of those items. These non-GAAP adjustments either do not reflect actual cash outlays that impact our liquidity and our financial condition or have a non-recurring impact on the statement of operations, as assessed by management. These non-GAAP financial measures are presented to permit investors to more fully understand how management assesses our performance for internal planning and forecasting purposes. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of our results of operations without including all items indicated above during a period, which may not provide a comparable view of our performance to other companies in our industry. Investors and other readers should consider non-GAAP measures only as supplements to, not as substitutes for or as superior measures to, the measures of financial performance prepared in accordance with GAAP. Reconciliation between results on a GAAP and non-GAAP basis is provided in a table below.

 

Yonah Lloyd

CCO, VP Investor Relations

Yonah.Lloyd@stratasys.com

Source: Stratasys Ltd.

 

3

 

 

Stratasys Ltd.

 

Consolidated Balance Sheets

(Unaudited)

(in thousands, except share data)

 

   June 30,   December 31, 
   2021   2020 
         
ASSETS        
         
Current assets        
Cash and cash equivalents  $343,733   $272,092 
Short-term deposits   179,000    27,000 
Accounts receivable, net of allowance for credit losses of $0.8 and $0.9 million as of June 30, 2021 and December 31, 2020   109,969    106,068 
Inventories   124,227    131,672 
Prepaid expenses   7,288    6,717 
Other current assets   21,189    16,943 
           
Total current assets   785,406    560,492 
           
Non-current assets          
Property, plant and equipment, net   201,080    201,232 
Goodwill   39,686    35,694 
Other intangible assets, net   124,257    131,569 
Operating lease right-of-use assets   17,514    21,298 
Other non-current assets   55,081    39,717 
           
Total non-current assets   437,618    429,510 
           
Total assets  $1,223,024   $990,002 
           
LIABILITIES AND EQUITY          
           
Current liabilities          
Accounts payable  $42,001   $16,987 
Accrued expenses and other current liabilities   30,134    31,061 
Accrued compensation and related benefits   29,270    25,659 
Deferred revenues - short term   48,943    49,165 
Operating lease liabilities - short term   8,248    9,282 
           
Total current liabilities   158,596    132,154 
           
Non-current liabilities          
Deferred revenues - long term   15,661    14,227 
Operating lease liabilities - long term   9,553    12,567 
Contingent consideration   40,436    37,400 
Other non-current liabilities   37,206    34,059 
           
Total non-current liabilities   102,856    98,253 
           
Total liabilities   261,452    230,407 
           
Redeemable non-controlling interests   227    227 
           
Equity          
Ordinary shares, NIS 0.01 nominal value, authorized 180,000 thousands shares; 65,396 thousands shares and 56,617 thousands shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively   181    155 
Additional paid-in capital   2,992,833    2,753,955 
Accumulated other comprehensive loss   (6,703)   (8,846)
Accumulated deficit   (2,024,966)   (1,985,896)
Total equity   961,345    759,368 
           
Total liabilities and equity  $1,223,024   $990,002 

 

4

 

 

Stratasys Ltd.

Consolidated Statements of Operations

(in thousands, except per share data)

 

   Three Months Ended
June 30,
   Six Months Ended
June 30,
 
   2021   2020   2021   2020 
   (unaudited)   (unaudited)   (unaudited)   (unaudited) 
Net sales                
Products  $100,305   $73,877   $190,629   $157,049 
Services   46,700    43,746    90,565    93,481 
    147,005    117,623    281,194    250,530 
                     
Cost of sales                    
Products   49,731    39,969    96,651    79,217 
Services   34,004    33,918    65,696    67,707 
    83,735    73,887    162,347    146,924 
                     
Gross profit   63,270    43,736    118,847    103,606 
                     
Operating expenses                    
Research and development, net   22,437    21,303    43,038    45,497 
Selling, general and administrative   63,557    51,711    116,891    107,287 
    85,994    73,014    159,929    152,784 
                     
Operating loss   (22,724)   (29,278)   (41,082)   (49,178)
                     
Financial income (expenses), net   (372)   149    (749)   (680)
                     
Loss before income taxes   (23,096)   (29,129)   (41,831)   (49,858)
                     
Income tax benefit   (4,368)   (2,128)   (5,310)   (1,907)
                     
Share in losses of associated companies   (1,431)   (950)   (2,549)   (1,788)
                     
Net loss   (20,159)   (27,951)   (39,070)   (49,739)
                     
Net income (loss) attributable to non-controlling interests   -    35    -    (50)
                     
Net loss attributable to Stratasys Ltd.  $(20,159)  $(27,986)  $(39,070)  $(49,689)
                     
Net loss per ordinary share attributable to Stratasys Ltd.                    
Basic  $(0.31)  $0.51   $(0.63)  $(0.91)
Diluted  $(0.31)  $0.51   $(0.63)  $(0.91)
                     
Weighted average ordinary shares outstanding                    
Basic   64,908    54,917    61,796    54,733 
Diluted   64,908    54,917    61,796    54,733 

 

5

 

 

      Three Months Ended June 30, 
      2021   Non-GAAP   2021   2020   Non-GAAP   2020 
      GAAP   Adjustments   Non-GAAP   GAAP   Adjustments   Non-GAAP 
      U.S. dollars and shares in thousands (except per share amounts) 
                            
   Gross profit (1)  $63,270   $6,616   $69,886   $43,736   $9,612   $53,348 
   Operating income (loss) (1,2)   (22,724)   20,133    (2,591)   (29,278)   21,228    (8,050)
   Net income (loss) attributable to Stratasys Ltd. (1,2,3)   (20,159)   18,581    (1,578)   (27,986)   20,634    (7,352)
   Net income (loss) per diluted share attributable to Stratasys Ltd. (4)  $(0.31)  $0.29   $(0.02)  $(0.51)  $0.38   $(0.13)
                                  
(1)  Acquired intangible assets amortization expense        5,518              4,065      
   Non-cash stock-based compensation expense        788              497      
   Restructuring and other related costs        310              5,050      
            6,616              9,612      
                                  
(2)  Acquired intangible assets amortization expense        2,200              2,125      
   Non-cash stock-based compensation expense        7,189              5,614      
   Restructuring and other related costs        350              3,798      
   Revaluation of investments        2,201              -      
   Contingent consideration        202              -      
   Other expenses        1,375              79      
            13,517              11,616      
            20,133              21,228      
                                  
(3)  Corresponding tax effect        (1,637)             (669)     
   Equity method related amortization, divestments and impairments        85              75      
           $18,581             $20,634      
                                  
(4)  Weighted average number of ordinary shares outstanding- Diluted   64,908         64,908    54,917         54,917 

 

6

 

 

      Six Months Ended June 30, 
      2021   Non-GAAP   2021   2020   Non-GAAP   2020 
      GAAP   Adjustments   Non-GAAP   GAAP   Adjustments   Non-GAAP 
      U.S. dollars and shares in thousands (except per share amounts) 
                            
   Gross profit (1)  $118,847   $13,685   $132,532   $103,606   $14,026   $117,632 
   Operating income (loss) (1,2)   (41,082)   35,918    (5,164)   (49,178)   32,719    (16,459)
   Net income (loss) attributable to Stratasys Ltd. (1,2,3)   (39,070)   33,692    (5,378)   (49,689)   31,771    (17,919)
   Net income (loss) per diluted share attributable to Stratasys Ltd. (4)  $(0.63)  $0.55   $(0.09)  $(0.91)  $0.58   $(0.33)
                                  
(1)  Acquired intangible assets amortization expense        10,873              8,130      
   Non-cash stock-based compensation expense        1,422              899      
   Restructuring and other related costs        1,390              4,997      
            13,685              14,026      
                                  
(2)  Acquired intangible assets amortization expense        4,393              4,267      
   Non-cash stock-based compensation expense        13,760              10,119      
   Restructuring and other related costs        2,159              3,829      
   Revaluation of investments        (1,469)             -      
   Contingent consideration        393              -      
   Other expenses        2,997              478      
            22,233              18,693      
            35,918              32,719      
                                  
(3)  Corresponding tax effect        (2,394)             (1,100)     
   Equity method related amortization, divestments and impairments        168              152      
           $33,692             $31,771      
                                  
(4)  Weighted average number of ordinary shares outstanding- Diluted   61,796        61,796    54,733        54,733 

 

7